Category: Uncategorized

After two years of stoppage due to the pandemic, ROVI’s employees have been able to resume their activity of face-to-face corporate volunteering to participate in the last edition of the Descent of the River of the River Sella Adapted, held last July 31 and organized by the Federation of Sports for People with Physical Disabilities of the Principality of Asturias (FEDEMA).

It is one of the forms of social work that our professionals like the most and consists of accompanying the athletes of the Foundation also during the tour in double canoe.

160 athletes participated in this event, 64 of whom were athletes with disabilities. They started the descent in the facilities of the Asturian School of Canoeing in Arriondas to complete the first non-competitive stretch of 10 kilometers until the revolt known as The Nail. There they made a stop before starting the competitive five-kilometer stretch, whose goal was located on the Feve bridge in Llovio (Ribadesella).

“It was an experience of great personal satisfaction and we would certainly repeat it,” said Raquel Martínez and Belén Paniagua, process engineering technicians at the Alcalá de Henares plant. “We were delighted that ROVI gave us the opportunity to support such a beautiful and necessary cause, and he could be a useful and supportive figure for the members of the Foundation TAMBIÉN. This edition has been very special for us, not only for the incredible experience lived with our colleagues, but for bringing us friends for life. “

The sporting event concluded with the award ceremony and a twinning meal for all participants at the Arriondas Municipal Sports Centre, in which the organizers thanked all the collaborators for their help, including the assistance services, which allowed the edition to be held without incident.

About his volunteer experience,Loreto Monleón, Quality Assurance technician at the San Sebastián de los Reyes plant, highlighted:“I think he has contributed a lot to both parties. I take home the affection, gratitude and friendship of the people we have helped to carry out an activity that would otherwise have been more difficult for them to carry out. They have taught me to see life in a much more optimistic way, and that the barriers are not to stop us, but to bring them down. “

Through its volunteer programme, ROVI continues to bet on promoting the inclusion of people with disabilities in the competitive sport arena, while providing unique life experiences to all those involved through its activities.

• Laboratorios Farmacéuticos ROVI, SA, (“ROVI”) has obtained the best ESG score from among the 458 companies evaluated in its pharmaceutical subindustry category.
• With an ESG risk rating of 17.3 points, ROVI remains in a low-risk position and shows an improvement of 1.1 points on the previous year’s rating (18.4 points).

In July 2022, the Environmental, Social and Governance (ESG) aspects of ROVI were evaluated by Sustainalytics, a leading independent ESG and corporate governance research, ratings and analytics firm that supports investors around the world with the development and implementation of responsible investment strategies. ROVI obtained the best rating from among the 458 companies evaluated in the pharmaceutical subindustry. This year, ROVI has obtained an ESG risk rating of 17.3 points, thus continuing in a low-risk position (between 10 and 20 points).

This rating shows an improvement of 1.1 points on last year’s rating (18.4 points) and places ROVI at the top of the ranking in its pharmaceutical subindustry worldwide. Among the 970 companies in the industry, which includes biotechnology companies, pharmaceutical laboratories and medical device companies, ROVI is in 22nd place.

Among the actions that have allowed ROVI to improve its rating in 2022, its commitment to the environment may be highlighted, due to the implementation of greenhouse gas reduction programmes and the use of renewable energy. Additionally, ROVI has been considered the sector leader in aspects such as the

oversight of material ESG issues by senior management and its anti-corruption / anti-bribery policy in the Corporate Governance chapter, together with, in the Social area, the implementation of a sound equality and non-discrimination policy.

ROVI’s rating may be consulted on the following link: https://www.rovi.es/sites/default/files/Laboratorios_Farmace%C3%BAticos_Rovi_SA_RiskRatingsSummaryReport_07_28_2022.pdf

• Operating revenue increased by 31% to 380.4 million euros driven by (i) the strength of the contract manufacturing organization (“CMO”) business, which grew by 76%, and (ii) the specialty pharmaceutical business, where sales rose 9%. 
• Sales of the heparin franchise (Low Molecular Weight Heparins (LMWH) and other heparins) increased by 8% to 141.6 million euros. Sales of the enoxaparin biosimilar increased 31% to 82.1 million euros and sales of Bemiparin decreased 14% to 55.8 million euros.
• EBITDA increased by 56% to 115.8 million euros.
• Net profit increased by 58% to 80.6 million euros.
• ROVI General Shareholders Meeting, on 14 June 2022, approved the payment of a gross dividend of 0.9556 euros per share on 2021 earnings; it means an increase of 151% compared to the dividend on 2020 earnings (€0.3812/share) and represents a 35% pay out. This dividend was paid on 7 July 2022.

END OF THE SHARE BUY-BACK PROGRAMMES AND CAPITAL REDUCTION THROUGH CANCELLATION OF SHARES

ROVI reported that, at its meeting of 22 February, 2022, the Board of Directors decided to end the first share buy-back programme, launched by the Company as of 3 November, 2021, having acquired a total of 1,492,108 ROVI shares, i.e. 89% of the maximum number of shares it had been initially planned to acquire under the buy-back programme.

Likewise, on 29 March, 2022, ROVI reported the end of the second buy-back programme, which had commenced on 23 February, 2022. A total of 560,700 treasury shares had been acquired, i.e. 100% of the maximum number it had been initially planned to acquire under the buy-back programme.

The purpose of the two buy-back programmes was to cancel treasury shares held by ROVI (by reducing the capital). The reduction of the capital through cancellation of 2,052,808 shares repurchased within the framework of the aforementioned buy-back programmes was approved at the General Shareholders’ Meeting of 14 June, 2022 and executed by entering the pertinent deed of capital reduction into public record. The deed is currently undergoing the registration process at the Madrid Companies Registry and the new amount of the share capital, after the shares mentioned have been cancelled and excluded from trading will appear in the registers of the National Securities Market Commission and Iberclear a few days after registration of the deed of capital reduction. The Company will provide further information in due course.

OUTLOOK

For 2022, ROVI expects its operating revenue to increase between 15% and 20%.

Don’t miss this 360º adventure through the office. Click on the image to start.

The European Investment Bank (EIB) is providing Laboratorios Farmacéuticos Rovi (ROVI) with a new EUR 50 million loan to finance its RDI activities for new developments in the ISM® prolonged drug-release technology, patented by ROVI, in fields such as oncology and the central nervous system, as well as the development and expansion of product applications in the glycomics field.

The agreement was signed in Madrid by Ricardo Mourinho Félix, European Investment Bank Vice-President, and the Chairman and CEO of ROVI, Juan López-Belmonte.

ROVI is a Spanish company specialised in researching, developing and marketing proprietary pharmaceuticals. It is currently participating in the manufacture of the active substance, as well as the fill & finish for the Moderna Covid-19 vaccine. ROVI is specialised in the manufacture of low-molecular-weight heparins (LMWHs), which the WHO recommends as essential medicines for patients hospitalised in intensive care units due to Covid-19.

The EIB loan helps to accelerate ROVI’s RDI strategy by supporting the investments of this highly innovative company. 

The financing will generate considerable positive externalities for the European pharmaceutical industry, contributing to the EU efforts to cover unmet health needs and secure qualified jobs.

Ricardo Mourinho Félix, European Investment Bank Vice-President said: “The EIB is committed to promoting RDI investment in Spain whilst helping preserve skilled employment. A European company that can significantly contribute to the solution of the current and future pandemics provides a significant strategic advantage for Europe and Spain. I am pleased that this loan will help ROVI to contribute to the competitive search to enhance pharmaceutical knowledge in Europe in areas that are important for the improvement of the health of its citizens”.

Juan López-Belmonte Encina, chairman and chief executive officer of ROVI, said: “Innovation and research form part of our identity as a pharmaceutical company, given that we bet on solutions that improve people’s health. At ROVI, we have a sound R&D strategy that makes us optimistic, since we hope that, as a result of the new launches, R&D will become one of the group’s strategic drivers in coming years. Therefore, the fact that the BEI has again placed its confidence in us so that we can continue to progress with our R&D projects represents a great opportunity for our company”.

Finance for research and development activities

The EIB’s loan will finance ROVI’s R&D activities in various drug delivery technologies with a particular focus on psychiatry and oncology, and the development and improvement of products in the glycomic area. It will also support pre-clinical and clinical development (clinical trials, regulatory approvals) research and development, market access and international roll-out of the company’s pipeline of in-house developed products.

Second EIB loan to ROVI

ROVI has been working with the EIB since 2017. Prior to this newly signed loan, the EIB had granted a EUR 45m loan to ROVI to finance its RDI programme focusing on technologies for the administration and extended release of medication related to treatments to fight cancer and nervous system diseases.

We want to share with you why you are so important to ROVI’s cyber security

The registration period for the XXI edition of the Descent of the Sella of the Fundación También is open. During the 29th, 30th and 31st of July you will be able to enjoy this unique activity with your colleagues.

VERY LIMITED PLACES

Eligibility requirements:

Please note that the activity focuses on accompanying a person with disabilities (motor, visual…) on a canoe trip along the Sella. For this reason, minimum physical abilities are required to do it safely. It is essential:

• Sporting experience
• Basic knowledge of canoeing

The foundation will make the final selection of volunteers according to the needs they have in accompanying its members.

Sign up HERE

You have until 12 July. If you have any doubts or queries, please ask Gonzalo Álvaro Saiz (galvaros@rovi.es).

Today, Laboratorios Farmacéuticos Rovi, S.A. held its Ordinary General Shareholders’ Meeting, at which the year 2021, marked by the company’s historic growth, was evaluated. ROVI achieved a 54% increase in its operating revenue. This increase was principally driven by the strength of the contract manufacturing business, which grew by 189%, and the specialty pharmaceutical business, whose sales rose 17%. “The year 2021 was historic for our company, which reaffirmed its original commitment to global health,” said Mr Juan López-Belmonte Encina, ROVI’s Chairman and Chief Executive Officer.

In his speech, he highlighted the value of the achievements reached in the year, which positioned ROVI as “one of the companies with the greatest knowledge in the low-molecular-heparin field and able to aspire to expand its global presence over the years to come.” Furthermore, in 2021, “ROVI continued to be the leader in specialty pharmaceuticals in Spain, while, as a result of the agreements with Modena, the contract manufacturing business gained a large amount of public visibility, confirming what we had always known: it is a strong driver that will help the company to grow in future years.”

The Chairman and CEO also highlighted “the work and commitment of the group’s employees overall” in reaching milestones that were important to ROVI in the year, such as achieving carbon neutrality for the second consecutive year or obtaining the second best score in the ESG ranking drawn up by the company Sustainalytics.

The Deputy Chairman and Chief Financial Officer, Javier López-Belmonte, provided an update on the R&D strategy of the company, “which is entering into a wonderful new phase after receiving the marketing approval for Europe of our first ISM®-technology-based drug.” He said that “our first large project with this technology, which was patented by ROVI, is a product for schizophrenia, a disease that affects over 21 million people worldwide” and added that “the application for marketing authorisation for Risperidone ISM® in the United States is awaiting the response of the United States regulatory authority.”

ROVI is working to reduce its environmental impact and, thanks to its Avoid, Reduce and Compensate strategy, has achieved CO2 neutrality.

Compensating emissions through the financing of high environmental impact projects by 2021 has been key to achieving these goals.

Do you want to know them? Don’t miss the following video.